Neuropathologic implication of peripheral neuregulin-1 and EGF signals in dopaminergic dysfunction and behavioral deficits relevant to schizophrenia: Their target cells and time window

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Nawa, Hiroyuki ^a   Sotoyama, Hidekazu ^a   Iwakura, Yuriko ^a   Takei, Nobuyuki ^a   Namba, Hisaaki ^a  

^a NIIGATA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; AMPHIREGULIN; DOPAMINE; DOPAMINE TRANSPORTER; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GELATINASE B; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 65; GLUTAMATE DECARBOXYLASE 67; GLUTAMIC ACID; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; HYDROGEN PEROXIDE; INTERLEUKIN 1; INTERLEUKIN 6; NEU DIFFERENTIATION FACTOR; PARVALBUMIN; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; TYROSINE 3 MONOOXYGENASE;

BEHAVIOR; BLOOD BRAIN BARRIER; BRAIN DEVELOPMENT; BRAIN NERVE CELL; CYTOKINE PRODUCTION; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; ENDOPHENOTYPE; ENZYME ACTIVITY; GENE EXPRESSION; GLOBUS PALLIDUS; HUMAN; LATENT INHIBITION; LOCOMOTION; NEUROPATHOLOGY; NONHUMAN; OLIGODENDROGLIA; PREFRONTAL CORTEX; PREPULSE INHIBITION; PROTEIN EXPRESSION; REVIEW; SCHIZOPHRENIA; SCHWANN CELL; SIGNAL TRANSDUCTION; SOCIAL BEHAVIOR; TRANSGENE; ANIMAL; ANIMAL BEHAVIOR; DRUG EFFECTS; METABOLISM; MOUSE; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; RAT;

ANIMALS; BEHAVIOR, ANIMAL; BLOOD-BRAIN BARRIER; DOPAMINE; DOPAMINERGIC NEURONS; EPIDERMAL GROWTH FACTOR; HUMANS; MICE; NEUREGULIN-1; NEURONS; RATS; SCHIZOPHRENIA;

EID: 84901763682     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/697935     Document Type: Review

References (78)

1. Cohen S., The epidermal growth factor (EGF). Cancer 1983 51 10 1787 1791 2-s2.0-0020583891 (Pubitemid 13093942)
2. Higashiyama S., Nanba D., ADAM-mediated ectodomain shedding of HB-EGF in receptor cross-talk. Biochimica et Biophysica Acta 2005 1751 1 110 117 2-s2.0-22744450061 10.1016/j.bbapap.2004.11.009 (Pubitemid 41033299)
3. Mei L., Xiong W.-C., Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nature Reviews Neuroscience 2008 9 6 437 452 2-s2.0-43949084738 10.1038/nrn2392 (Pubitemid 351704944)
4. Futamura T., Toyooka K., Iritani S., Niizato K., Nakamura R., Tsuchiya K., Someya T., Kakita A., Takahashi H., Nawa H., Abnormal expression of epidermal growth factor and its receptor in the forebrain and serum of schizophrenic patients. Molecular Psychiatry 2002 7 7 673 682 2-s2.0-0036367363 10.1038/sj.mp.4001081 (Pubitemid 34984943)
5. Shibuya M., Komi E., Wang R., Kato T., Watanabe Y., Sakai M., Ozaki M., Someya T., Nawa H., Measurement and comparison of serum neuregulin 1 immunoreactivity in control subjects and patients with schizophrenia: an influence of its genetic polymorphism. Journal of Neural Transmission 2010 117 7 887 895 2-s2.0-77954543574 10.1007/s00702-010-0418-3
6. Jeng D., Ma Z., Barrett J. W., McFadden G., Loeb J. A., Essani K., The tanapoxvirus 15L protein is a virus-encoded neuregulin that promotes viral replication in human endothelial cells. Journal of Virology 2013 87 6 3018 3026
7. Kim M., Yang H., Kim S. K., Reche P. A., Tirabassi R. S., Hussey R. E., Chishti Y., Rheinwald J. G., Morehead T. J., Zech T., Damon I. K., Welsh R. M., Reinherz E. L., Biochemical and functional analysis of smallpox growth factor (SPGF) and anti-SPGF monoclonal antibodies. Journal of Biological Chemistry 2004 279 24 25838 25848 2-s2.0-2942621884 10.1074/jbc.M400343200 (Pubitemid 38756849)
8. Galvez-Contreras A. Y., Quiñones-Hinojosa A., Gonzalez-Perez O., The role of EGFR and ErbB family related proteins in the oligodendrocyte specification in germinal niches of the adult mammalian brain. Frontiers in Cellular Neuroscince 2013 7, article 258
9. Xian C. J., Zhou X. F., EGF family of growth factors: essential roles and functional redundancy in the nerve system. Frontiers in Bioscience 2004 9 85 92 2-s2.0-2542459332 (Pubitemid 38925441)
10. Nawa H., Takei N., Recent progress in animal modeling of immune inflammatory processes in schizophrenia: implication of specific cytokines. Neuroscience Research 2006 56 1 2 13 2-s2.0-33748616003 10.1016/j.neures.2006. 06.002 (Pubitemid 44376487)
11. Iwakura Y., Nawa H., ErbB1-4-dependent EGF/neuregulin signals and their cross talk in the central nervous system: pathological implications in schizophrenia and Parkinson's disease. Frontiers in Cellular Neuroscince 2013 7, article 4
12. Jo M., Stolz D. B., Esplen J. E., Dorko K., Michalopoulos G. K., Strom S. C., Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. Journal of Biological Chemistry 2000 275 12 8806 8811 2-s2.0-0034708826 10.1074/jbc.275.12.8806 (Pubitemid 30180235)
13. Kornblum H. I., Yanni D. S., Easterday M. C., Seroogy K. B., Expression of the EGF receptor family members ErbB2, ErbB3, and ErbB4 in germinal zones of the developing brain and in neurosphere cultures containing CNS stem cells. Developmental Neuroscience 2000 22 1-2 16 24 2-s2.0-0033976324 (Pubitemid 30098902)
14. Fox I. J., Kornblum H. I., Developmental profile of ErbB receptors in murine central nervous system: implications for functional interactions. Journal of Neuroscience Research 2005 79 5 584 597 2-s2.0-16444383812 10.1002/jnr.20381 (Pubitemid 40476437)
15. Abe Y., Namba H., Zheng Y., Nawa H., In situ hybridization reveals developmental regulation of ErbB1-4 mRNA expression in mouse midbrain: implication of ErbB receptors for dopaminergic neurons. Neuroscience 2009 161 1 95 110 2-s2.0-67349232018 10.1016/j.neuroscience.2009.03.022
16. Neddens J., Fish K. N., Tricoire L., Vullhorst D., Shamir A., Chung W., Lewis D. A., McBain C. J., Buonanno A., Conserved interneuron-specific ErbB4 expression in frontal cortex of rodents, monkeys, and humans: implications for schizophrenia. Biological Psychiatry 2011 70 7 636 645 2-s2.0-80052863881 10.1016/j.biopsych.2011.04.016
17. Nagano T., Namba H., Abe Y., Aoki H., Takei N., Nawa H., In vivo administration of epidermal growth factor and its homologue attenuates developmental maturation of functional excitatory synapses in cortical GABAergic neurons. European Journal of Neuroscience 2007 25 2 380 390 2-s2.0-33847013040 10.1111/j.1460-9568.2007.05297.x
18. Birchmeier C., Nave K. A., Neuregulin-1, a key axonal signal that drives Schwann cell growth and differentiation. Glia 2008 56 14 1491 1497 2-s2.0-61549136754
19. Zhang L., Fletcher-Turner A., Marchionni M. A., Apparsundaram S., Lundgren K. H., Yurek D. M., Seroogy K. B., Neurotrophic and neuroprotective effects of the neuregulin glial growth factor-2 on dopaminergic neurons in rat primary midbrain cultures. Journal of Neurochemistry 2004 91 6 1358 1368 2-s2.0-7044253710 10.1111/j.1471-4159.2004.02817.x (Pubitemid 39658562)
20. Iwakura Y., Wang R., Abe Y., Piao Y.-S., Shishido Y., Higashiyama S., Takei N., Nawa H., Dopamine-dependent ectodomain shedding and release of epidermal growth factor in developing striatum: target-derived neurotrophic signaling (Part 2). Journal of Neurochemistry 2011 118 1 57 68 2-s2.0-79958790544 10.1111/j.1471-4159.2011.07295.x
21. Carlsson T., Schindler F. R., Höllerhage M., Depboylu C., Arias-Carrión O., Schnurrbusch S., Rösler T. W., Wozny W., Schwall G. P., Groebe K., Oertel W. H., Brundin P., Schrattenholz A., Höglinger G. U., Systemic administration of neuregulin-1 β 1 protects dopaminergic neurons in a mouse model of Parkinson's disease. Journal of Neurochemistry 2011 117 6 1066 1074 2-s2.0-79957999312 10.1111/j.1471-4159.2011.07284.x
22. Fazzari P., Paternain A. V., Valiente M., Pla R., Luján R., Lloyd K., Lerma J., Marín O., Rico B., Control of cortical GABA circuitry development by Nrg1 and ErbB4 signalling. Nature 2010 464 7293 1376 1380 2-s2.0-77951879644 10.1038/nature08928
23. Ting A. K., Chen Y., Wen L., Yin D.-M., Shen C., Tao Y., Liu X., Xiong W.-C., Mei L., Neuregulin 1 promotes excitatory synapse development and function in GABAergic interneurons. Journal of Neuroscience 2011 31 1 15 25 2-s2.0-78650860729 10.1523/JNEUROSCI.2538-10.2011
24. Abe Y., Namba H., Kato T., Iwakura Y., Nawa H., Neuregulin-1 signals from the periphery regulate AMPA receptor sensitivity and expression in GABAergic interneurons in developing neocortex. Journal of Neuroscience 2011 31 15 5699 5709 2-s2.0-79955775947 10.1523/JNEUROSCI.3477-10.2011
25. Stefansson H., Sigurdsson E., Steinthorsdottir V., Bjornsdottir S., Sigmundsson T., Ghosh S., Brynjolfsson J., Gunnarsdottir S., Ivarsson O., Chou T. T., Hjaltason O., Birgisdottir B., Jonsson H., Gudnadottir V. G., Gudmundsdottir E., Bjornsson A., Ingvarsson B., Ingason A., Sigfusson S., Hardardottir H., Harvey R. P., Lai D., Zhou M., Brunner D., Mutel V., Gonzalo A., Lemke G., Sainz J., Johannesson G., Andresson T., Gudbjartsson D., Manolescu A., Frigge M. L., Gurney M. E., Kong A., Gulcher J. R., Petursson H., Stefansson K., Neuregulin 1 and Susceptibility to Schizophrenia. The American Journal of Human Genetics 2002 71 4 877 892 2-s2.0-0013375948 (Pubitemid 135750519)
26. Anttila S., Illi A., Kampman O., Mattila K. M., Lehtimäki T., Leinonen E., Association of EGF polymorphism with schizophrenia in Finnish men. NeuroReport 2004 15 7 1215 1218 2-s2.0-2442692638 10.1097/00001756-200405190- 00027 (Pubitemid 38670084)
27. Lee K. Y., Ahn Y. M., Joo E. J., Joo Y. H., Chang J. S., Yoo H. Y., Kim Y. S., Partial evidence of an association between epidermal growth factor A61G polymorphism and age at onset in male schizophrenia. Neuroscience Research 2006 56 4 356 362 2-s2.0-33751021702 10.1016/j.neures.2006.08.004 (Pubitemid 44750263)
28. Hänninen K., Katila H., Anttila S., Rontu R., Maaskola J., Hurme M., Lehtimäki T., Epidermal growth factor a61g polymorphism is associated with the age of onset of schizophrenia in male patients. Journal of Psychiatric Research 2007 41 1-2 8 14 2-s2.0-33750743040 10.1016/j.jpsychires.2005.07.001 (Pubitemid 44708202)
29. Watanabe Y., Fukui N., Muratake T., Kaneko N., Someya T., No association of EGF polymorphism with schizophrenia in a Japanese population. NeuroReport 2005 16 4 403 405 2-s2.0-15944399455 10.1097/00001756-200503150-00019 (Pubitemid 40434574)
30. Tohmi M., Tsuda N., Mizuno M., Takei N., Frankland P. W., Nawa H., Distinct influences of neonatal epidermal growth factor challenge on adult neurobehavioral traits in four mouse strains. Behavior Genetics 2005 35 5 615 629 2-s2.0-25144450023 10.1007/s10519-005-5357-7 (Pubitemid 41355979)
31. Futamura T., Kakita A., Tohmi M., Sotoyama H., Takahashi H., Nawa H., Neonatal perturbation of neurotrophic signaling results in abnormal sensorimotor gating and social interaction in adults: implication for epidermal growth factor in cognitive development. Molecular Psychiatry 2003 8 19 29 (Pubitemid 36188570)
32. Mizuno M., Malta R. S. Jr., Nagano T., Nawa H., Conditioned place preference and locomotor sensitization after repeated administration of cocaine or methamphetamine in rats treated with epidermal growth factor during the neonatal period. Annals of the New York Academy of Sciences 2004 1025 612 618 2-s2.0-10444259012 10.1196/annals.1316.076 (Pubitemid 39643915)
33. Sotoyama H., Namba H., Takei N., Nawa H., Neonatal exposure to epidermal growth factor induces dopamine D 2-like receptor supersensitivity in adult sensorimotor gating. Psychopharmacology 2007 191 3 783 792 2-s2.0-33847610284 10.1007/s00213-006-0595-9 (Pubitemid 46355897)
34. Watanabe Y., Hashimoto S., Kakita A., Takahashi H., Ko J., Mizuno M., Someya T., Patterson P. H., Nawa H., Neonatal impact of leukemia inhibitory factor on neurobehavioral development in rats. Neuroscience Research 2004 48 3 345 353 2-s2.0-1242293704 10.1016/j.neures.2003.12.001 (Pubitemid 38220952)
35. Tohmi M., Tsuda N., Watanabe Y., Kakita A., Nawa H., Perinatal inflammatory cytokine challenge results in distinct neurobehavioral alterations in rats: implication in psychiatric disorders of developmental origin. Neuroscience Research 2004 50 1 67 75 2-s2.0-3543121321 10.1016/j.neures.2004. 05.010 (Pubitemid 39024303)
36. Tohmi M., Tsuda N., Zheng Y., Mizuno M., Sotoyama H., Shibuya M., Kawamura M., Kakita A., Takahashi H., Nawa H., The cellular and behavioral consequences of interleukin-1 alpha penetration through the blood-brain barrier of neonatal rats: a critical period for efficacy. Neuroscience 2007 150 1 234 250 2-s2.0-36649010971 10.1016/j.neuroscience.2007.08.034 (Pubitemid 350198691)
37. Tsuda N., Mizuno M., Yamanaka T., Komurasaki T., Yoshimoto M., Nawa H., Common behavioral influences of the ErbB1 ligands transforming growth factor alpha and epiregulin administered to mouse neonates. Brain and Development 2008 30 8 533 543 2-s2.0-47149110256 10.1016/j.braindev.2008.01.006
38. Kato T., Abe Y., Sotoyama H., Kakita A., Kominami R., Hirokawa S., Ozaki M., Takahashi H., Nawa H., Transient exposure of neonatal mice to neuregulin-1 results in hyperdopaminergic states in adulthood: implication in neurodevelopmental hypothesis for schizophrenia. Molecular Psychiatry 2011 16 3 307 320 2-s2.0-79951811861 10.1038/mp.2010.10
39. Kleshcheva R. P., The development of components of the blood-brain barrier in the neocortex of the white rat. Arkhiv Anatomii, Gistologii i Embriologii 1988 95 11 22 26 2-s2.0-0024118121
40. Kastin A. J., Akerstrom V., Pan W., Neuregulin-1- β 1 enters brain and spinal cord by receptor-mediated transport. Journal of Neurochemistry 2004 88 4 965 970 2-s2.0-1042289645 (Pubitemid 38199318)
41. Rösler T. W., Depboylu C., Arias-Carrión O., Wozny W., Carlsson T., Höllerhage M., Oertel W. H., Schrattenholz A., Höglinger G. U., Biodistribution and brain permeability of the extracellular domain of neuregulin-1- β 1. Neuropharmacology 2011 61 8 1413 1418 2-s2.0-80053595301 10.1016/j.neuropharm.2011.08.033
42. Seroogy K. B., Numan S., Gall C. M., Lee D. C., Kornblum H. I., Expression of EGF receptor mRNA in rat nigrostriatal system. NeuroReport 1994 6 1 105 108 2-s2.0-0028608105
43. Mizuno M., Sotoyama H., Narita E., Kawamura H., Namba H., Zheng Y., Eda T., Nawa H., A cyclooxygenase-2 inhibitor ameliorates behavioral impairments induced by striatal administration of epidermal growth factor. Journal of Neuroscience 2007 27 38 10116 10127 2-s2.0-34548834700 10.1523/JNEUROSCI.2368- 07.2007 (Pubitemid 47450461)
44. Sakai M., Kashiwahara M., Kakita A., Nawa H., An attempt of non-human primate modeling of schizophrenia with neonatal challenges of epidermal growth factor. Behavioral Pharmacology in Addiction Research & Therapy 2014 5, article 170 10.4172/2155-6105.1000170
45. Kato T., Kasai A., Mizuno M., Fengyi L., Shintani N., Maeda S., Yokoyama M., Ozaki M., Nawa H., Phenotypic characterization of transgenic mice overexpressing neuregulin-1. PLoS ONE 2010 5 12 2-s2.0-78650083166 10.1371/journal.pone.0014185 e14185
46. Eda T., Mizuno M., Araki K., Iwakura Y., Namba H., Sotoyama H., Kakita A., Takahashi H., Satoh H., Chan S. Y., Nawa H., Neurobehavioral deficits of epidermal growth factor-overexpressing transgenic mice: impact on dopamine metabolism. Neuroscience Letters 2013 547 21 25
47. O'Tuathaigh C. M., Babovic D., O'Meara G., Clifford J. J., Croke D. T., Waddington J. L., Susceptibility genes for schizophrenia: characterisation of mutant mouse models at the level of phenotypic behaviour. Neuroscience and Biobehavioral Reviews 2007 31 1 60 78 2-s2.0-33845329226 10.1016/j.neubiorev. 2006.04.002 (Pubitemid 44880074)
48. Mouri A., Nagai T., Ibi D., Yamada K., Animal models of schizophrenia for molecular and pharmacological intervention and potential candidate molecules. Neurobiology of Disease 2013 53 61 74
49. Karl T., Neuregulin 1: a prime candidate for research into gene-environment interactions in schizophrenia? Insights from genetic rodent models. Frontiers in Behavioral Neuroscience 2013 7, article 106
50. Oyagi A., Oida Y., Kakefuda K., Shimazawa M., Shioda N., Moriguchi S., Kitaichi K., Nanba D., Yamaguchi K., Furuta Y., Fukunaga K., Higashiyama S., Hara H., Generation and characterization of conditional heparin-binding EGF-like growth factor knockout mice. PLoS ONE 2009 4 10 2-s2.0-70449338128 10.1371/journal.pone.0007461 e7461
51. Hahn C. G., Wang H. Y., Cho D. S., Talbot K., Gur R. E., Berrettini W. H., Bakshi K., Kamins J., Borgmann-Winter K. E., Siegel S. J., Gallop R. J., Arnold S. E., Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nature Medicine 2006 12 7 824 828 2-s2.0-33745912772 10.1038/nm1418 (Pubitemid 44050073)
52. Karl T., Duffy L., Scimone A., Harvey R. P., Schofield P. R., Altered motor activity, exploration and anxiety in heterozygous neuregulin 1 mutant mice: Implications for understanding schizophrenia. Genes, Brain and Behavior 2007 6 7 677 687 2-s2.0-34748906661 10.1111/j.1601-183X.2006.00298.x (Pubitemid 47476190)
53. del Pino I., García-Frigola C., Dehorter N., Brotons-Mas J. R., Alvarez-Salvado E., Martínez de Lagrán M., Ciceri G., Gabaldón M. V., Moratal D., Dierssen M., Canals S., Marín O., Rico B., ErbB4 deletion from fast-spiking interneurons causes schizophrenia-like phenotypes. Neuron 2013 79 6 1152 1168
54. Watanabe Y., Someya T., Nawa H., Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models. Psychiatry and Clinical Neurosciences 2010 64 3 217 230 2-s2.0-77952569813 10.1111/j.1440-1819. 2010.02094.x
55. Namba H., Nagano T., Iwakura Y., Xiong H., Jourdi H., Takei N., Nawa H., Transforming growth factor alpha attenuates the functional expression of AMPA receptors in cortical GABAergic neurons. Molecular and Cellular Neuroscience 2006 31 4 628 641 2-s2.0-33645374580 10.1016/j.mcn.2005.12.002
56. Namba H., Zheng Y., Abe Y., Nawa H., Epidermal growth factor administered in the periphery influences excitatory synaptic inputs onto midbrain dopaminergic neurons in postnatal mice. Neuroscience 2009 158 4 1731 1741 2-s2.0-60149095741 10.1016/j.neuroscience.2008.10.057
57. Yokomaku D., Jourdi H., Kakita A., Nagano T., Takahashi H., Takei N., Nawa H., ErbB1 receptor ligands attenuate the expression of synaptic scaffolding proteins, GRIP1 and SAP97, in developing neocortex. Neuroscience 2005 136 4 1037 1047 2-s2.0-29044435611 10.1016/j.neuroscience.2005.08.014 (Pubitemid 41790519)
58. Sotoyama H., Zheng Y., Iwakura Y., Mizuno M., Aizawa M., Shcherbakova K., Wang R., Namba H., Nawa H., Pallidal hyperdopaminergic innervation underlying d2 receptor-dependent behavioral deficits in the schizophrenia animal model established by EGF. PLoS ONE 2011 6 10 2-s2.0-80053957614 10.1371/journal.pone. 0025831 e25831
59. Zheng Y., Watakabe A., Takada M., Kakita A., Namba H., Takahashi H., Yamamori T., Nawa H., Expression of ErbB4 in substantia nigra dopamine neurons of monkeys and humans. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2009 33 4 701 706 2-s2.0-67349159854 10.1016/j.pnpbp.2009.03.021
60. Deakin I. H., Nissen W., Law A. J., Lane T., Kanso R., Schwab M. H., Nave K. A., Lamsa K. P., Paulsen O., Bannerman D. M., Harrison P. J., Transgenic overexpression of the type I isoform of neuregulin 1 affects working memory and hippocampal oscillations but not long-term potentiation. Cerebral Cortex 2012 22 7 1520 1529
61. Yin D. M., Chen Y. J., Lu Y. S., Bean J. C., Sathyamurthy A., Shen C., Liu X., Lin T. W., Smith C. A., Xiong W. C., Mei L., Reversal of behavioral deficits and synaptic dysfunction in mice overexpressing neuregulin 1. Neuron 2013 78 4 644 657
62. Luo X., He W., Hu X., Yan R., Reversible overexpression of Bace1-cleaved neuregulin-1 N-terminal fragment induces schizophrenia-like phenotypes in mice. Biological Psychiatry 2013 10.1016/j.biopsych.2013.09.026
63. Perreault M. L., Hasbi A., Alijaniaram M., Fan T., Varghese G., Fletcher P. J., Seeman P., O'Dowd B. F., George S. R., The dopamine D1-D2 receptor heteromer localizes in dynorphin/enkephalin neurons: Increased high affinity state following amphetamineandin schizophrenia. Journal of Biological Chemistry 2010 285 47 36625 36634 2-s2.0-78449246412 10.1074/jbc.M110.159954
64. Gerfen C. R., Surmeier D. J., Modulation of striatal projection systems by dopamine. Annual Review of Neuroscience 2011 34 441 466 2-s2.0-79959869606 10.1146/annurev-neuro-061010-113641
65. Cazorla M., de Carvalho F. D., Chohan M. O., Shegda M. M., Chuhma N., Rayport S., Ahmari S. E., Moore H., Kellendonk C., Dopamine d2 receptors regulate the anatomical and functional balance of Basal Ganglia circuitry. Neuron 2014 81 1 153 164
66. Sotoyama H., Namba H., Chiken S., Nambu A., Nawa H., Exposure to the cytokine EGF leads to abnormal hyperactivity of pallidal GABA neurons: implications for schizophrenia and its modeling. Journal of Neurochemistry 2013 126 4 518 528
67. Mizuno M., Sotoyama H., Namba H., Shibuya M., Eda T., Wang R., Okubo T., Nagata K., Iwakura Y., Nawa H., ErbB inhibitors ameliorate behavioral impairments of an animal model for schizophrenia: implication of their dopamine-modulatory actions. Translational Psychiatry 2013 3, article e252
68. Levy D. L., Sereno A. B., Gooding D. C., O'Driscoll G. A., Eye tracking dysfunction in schizophrenia: characterization and pathophysiology. Current Topics in Behavioral Neurosciences 2010 4 311 347 2-s2.0-79952265243 10.1007/7854-2010-60
69. Furman M., Gur M., And yet it moves: perceptual illusions and neural mechanisms of pursuit compensation during smooth pursuit eye movements. Neuroscience and Biobehavioral Reviews 2012 36 1 143 151 2-s2.0-82855165194 10.1016/j.neubiorev.2011.05.005
70. Higashiyama S., Nanba D., Nakayama H., Inoue H., Fukuda S., Ectodomain shedding and remnant peptide signalling of EGFRs and their ligands. Journal of Biochemistry 2011 150 1 15 22 2-s2.0-79960102280 10.1093/jb/mvr068
71. Schneider M. R., Wolf E., The epidermal growth factor receptor ligands at a glance. Journal of Cellular Physiology 2009 218 3 460 466 2-s2.0-58149376976 10.1002/jcp.21635
72. Crawford H. C., Dempsey P. J., Brown G., Adam L., Moss M. L., ADAM10 as a therapeutic target for cancer and inflammation. Current Pharmaceutical Design 2009 15 20 2288 2299 2-s2.0-69249152227 10.2174/138161209788682442
73. Peng L., Li B., Du T., Kong E. K. C., Hu X., Zhang S., Shan X., Zhang M., Astrocytic transactivation by α 2A-adrenergic and 5-HT2B serotonergic signaling. Neurochemistry International 2010 57 4 421 431 2-s2.0-77956228965 10.1016/j.neuint.2010.04.018
74. Iwakura Y., Zheng Y., Sibilia M., Abe Y., Piao Y.-S., Yokomaku D., Wang R., Ishizuka Y., Takei N., Nawa H., Qualitative and quantitative re-evaluation of epidermal growth factor-ErbB1 action on developing midbrain dopaminergic neurons in vivo and in vitro: target-derived neurotrophic signaling (Part 1). Journal of Neurochemistry 2011 118 1 45 56 2-s2.0-79958780862 10.1111/j.1471-4159.2011.07287.x
75. Yoon S., Baik J. H., Dopamine D2 receptor-mediated epidermal growth factor receptor transactivation through a disintegrin and metalloprotease regulates dopaminergic neuron development via extracellular signal-related kinase activation. The Journal of Biological Chemistry 2013 288 40 28435 28446
76. O'Keeffe G. C., Tyers P., Aarsland D., Dalley J. W., Barker R. A., Caldwellf M. A., Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF. Proceedings of the National Academy of Sciences of the United States of America 2009 106 21 8754 8759 2-s2.0-66649120006 10.1073/pnas.0803955106
77. Meyer U., Feldon J., Yee B. K., A review of the fetal brain cytokine imbalance hypothesis of schizophrenia. Schizophrenia Bulletin 2009 35 5 959 972 2-s2.0-69249107681 10.1093/schbul/sbn022
78. Bauer S., Kerr B. J., Patterson P. H., The neuropoietic cytokine family in development, plasticity, disease and injury. Nature Reviews Neuroscience 2007 8 3 221 232 2-s2.0-33847111695 10.1038/nrn2054 (Pubitemid 46294661)